{"id":"adalimumab-and-its-biosimilars","safety":{"commonSideEffects":[{"rate":"12-20%","effect":"Injection site reactions"},{"rate":"7-15%","effect":"Upper respiratory tract infections"},{"rate":"5-12%","effect":"Headache"},{"rate":"0.1-0.5%","effect":"Tuberculosis reactivation"},{"rate":"1-3%","effect":"Serious infections"},{"rate":"increased relative risk","effect":"Malignancy risk"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By blocking TNF-α, adalimumab reduces inflammatory signaling and immune activation in conditions driven by excessive TNF-α production. This leads to decreased inflammation, reduced immune cell infiltration, and clinical improvement in autoimmune and inflammatory diseases. Biosimilars are biologically equivalent versions manufactured by different companies with comparable efficacy and safety profiles.","oneSentence":"Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:24:48.745Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"},{"name":"Ankylosing spondylitis"},{"name":"Psoriatic arthritis"},{"name":"Psoriasis"},{"name":"Hidradenitis suppurativa"},{"name":"Juvenile idiopathic arthritis"}]},"trialDetails":[{"nctId":"NCT07221890","phase":"NA","title":"A Trial of Academic Detailing to Promote Prescribing of Biosimilars","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2025-11-06","conditions":"Autoimmune Diseases, Rheumatoid Arthritis (RA), Inflammatory Bowel Disease (IBD)","enrollment":1325},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT04655807","phase":"PHASE2","title":"A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease","status":"WITHDRAWN","sponsor":"Janssen Research & Development, LLC","startDate":"2021-03-03","conditions":"Crohn Disease","enrollment":""},{"nctId":"NCT03983876","phase":"PHASE1","title":"PK, Safety and Tolerability Study of AVT02 (Adalimumab) Pre-filled Syringe (PFS) vs, AVT02 Autoinjector (AI)","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2019-07-01","conditions":"Phase 1","enrollment":207},{"nctId":"NCT03849313","phase":"PHASE1","title":"Pharmacokinetics, Safety and Tolerability Study of AVT02 to EU-approved and US-licensed Humira (Adalimumab)","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2019-03-20","conditions":"Healthy Volunteers","enrollment":390},{"nctId":"NCT05164198","phase":"PHASE4","title":"REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST)","status":"UNKNOWN","sponsor":"Hanyang University Seoul Hospital","startDate":"2022-01-15","conditions":"Ankylosing Spondylitis, Axial Spondyloarthritis","enrollment":448},{"nctId":"NCT04422171","phase":"","title":"A 12-month Real Life Study of IBD Patients Switched From Adalimumab Originator Humira® to One of Its Biosimilar","status":"UNKNOWN","sponsor":"University Hospital, Grenoble","startDate":"2020-06-19","conditions":"IBD Patients, Originator Treatment, Biosimilar, Switch Back","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":462,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Humira","Adaloce"],"phase":"marketed","status":"active","brandName":"Adalimumab and its biosimilars","genericName":"Adalimumab and its biosimilars","companyName":"Hanyang University Seoul Hospital","companyId":"hanyang-university-seoul-hospital","modality":"Biologic","firstApprovalDate":"","aiSummary":"Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine. Used for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}